SCHEMBL20394339

SCHEMBL20394339

Cc1noc(C)c1-c1cccnc1Oc1ccc(C(C)(F)F)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 8/20 0.40
FFAR1 O14842 2/20 0.37
BRD2 P25440 2/20 0.36
CREBBP Q92793 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
NSD3 Q9BZ95 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP2C19 P33261 1/20 0.34
DRD1 P21728 2/20 0.34
GPBAR1 Q8TDU6 1/20 0.34
AURKA O14965 1/20 0.33
AURKB Q96GD4 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPK1 P28482 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394498 0.83 ALDH1A1 (0.32) ALDH1A1DRD1
SCHEMBL20394248 0.83 BRD4 (0.37) BRD4ALDH1A1CYP2C19DRD1CYP1A2
SCHEMBL20394258 0.80 DRD1 (0.34) ALDH1A1DRD1
SCHEMBL18661513 0.79 PDE10A (0.42) GPBAR1
SCHEMBL18661454 0.78 PDE10A (0.35) DRD1
SCHEMBL20406568 0.77 DRD1 (0.38) ALDH1A1DRD1
SCHEMBL20394327 0.76 CYP17A1 (0.38) DRD1CYP1A2
SCHEMBL20394302 0.76 PDE10A (0.36)
SCHEMBL20406756 0.76 BRD4 (0.43) BRD4FFAR1BRD2CREBBPALDH1A1
SCHEMBL18661516 0.75 PDE10A (0.45) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA BRD4 145/4885FFAR1 2327/4885BRD2 69/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA BRD4 145/4885FFAR1 2327/4885BRD2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.